CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock



Company Profile

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Financial figures, Fiscal year: from 01.01. to 31.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 1,366,426,000,000 1,336,537,000,000 1,063,661,000,000 73,202,000,000 73,202,000,000 Common stock capital 73,202,000,000 **Fixed assets** 566,121,000,000 475,033,000,000 533,221,000,000 Equity capital of a company 1,625,580,000,000 1,424,387,000,000 1,188,017,000,000 458 674 000 000 222 169 000 000 267 753 000 000 Cash and cash equivalents Accrued liabilities 5.739.000.000 6.067.000.000 5.046.000.000 Other assets **Current liabilities** 288,217,000,000 423.730.000.000 327.422.000.000 Prepayments and accrued income Non-current liabilities 18,749,000,000 21,641,000,000 23,255,000,000

Different income		-		-		-
Other liabilities		743,000,000		813,000,000		1,105,000,000
Total assets	1,932,547,000,000	1,932,547,000,000	1,869,758,000,000	1,869,758,000,000	1,538,694,000,000	1,538,694,000,000
Balance notes						
				2023	2022	2021
Accounting standard				IFRS	IFRS	IFRS
Employees				7,604	7,771	7,664
Equity ratio				84.12%	76.18%	77.21%
Debt-equity ratio				18.88%	31.27%	29.52%
Others						
				2023	2022	2021
Tax Expense Rate				26.67%	29.51%	27.75%

CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	1,111,367,000,000	1,259,946,000,000	999,758,000,000
Net income	325,472,000,000	374,429,000,000	302,995,000,000
EBIT	2,696,962,500	3,239,368,400	2,557,534,800
Operating income before taxes	443,821,000,000	531,166,000,000	419,385,000,000
Cash Flow	411,326,000,000	244,335,000,000	279,711,000,000
Net interest income	1,696,000,000	122,000,000	117,000,000
Research and development expenses	164,764,000,000	148,360,000,000	131,276,000,000
Income taxes	118,349,000,000	156,737,000,000	116,390,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	891,549	989,020	795,736

Board of Directors	
Christoph Franz	Member of Supervisory Board
James Sabry	Member of Supervisory Board
Iwaaki Taniguchi	Member of Supervisory Board
Mariko Momoi	Member of Supervisory Board
Masayuki Oku	Member of Supervisory Board
Motoo Ueno	Member of Supervisory Board
William Anderson	Member of Supervisory Board
Yoichiro Ichimaru	Member of Supervisory Board

Members of Management Board				
Osamu Okuda	Chairman of Managing Board			
Hisafumi Yamada	Member of Executive Committee			
Junichi Ebihara	Member of Executive Committee			
Satoko Shisai	Member of Executive Committee			
Shinji Hidaka	Member of Executive Committee			
Tetsuya Yamaguchi	Member of Executive Committee			
Toshiaki Itagaki	Member of Executive Committee			
Yoshiyuki Yano	Member of Executive Committee			